Xenon Pharma Webinar: Deep Dive into Kv7 & Nav1.7 Pain Programs
Xenon Pharmaceuticals is hosting an investor webinar, focusing on its Kv7 and Nav1.7 programs for pain treatment. Dr. Jim Empfield, Executive Vice President of Drug Discovery, will lead the discussion, delving into the company's history and ion channel drug development, particularly in pain treatment. Dr. Chris Kenney, Chief Medical Officer, and Dr. JP Gilbert, Senior Director of Biology, will also participate.
Dr. Jim Empfield, with Xenon for nearly a decade, has spearheaded the buildout of its discovery function. Before joining Xenon, he served at Bristol-Myers Squibb and Vertex in Boston, where he held roles such as Vice President, Drug Discovery and Chemistry, and co-site Head of Research.
Ian Mortimer, Xenon's interim CFO and President, will provide a corporate overview and discuss the current pipeline. Forward-looking statements will be made during the webinar, and listeners are advised to review Xenon's SEC filings for risk discussions.
The webinar, centered around Xenon's Kv7 and Nav1.7 programs for pain treatment, will offer insights into the company's drug discovery process and pipeline. With experienced speakers like Dr. Jim Empfield, Dr. Chris Kenney, and Dr. JP Gilbert, the event promises valuable information for investors and industry enthusiasts.
